Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

7 evidence topics · 8 sources

RAPIDe-3: concomitant long-term prophylaxis permitted
RAPIDe-3: long-term prophylaxis agents used by participants who treated at least one attack
Long-term prophylaxisDeucrictibant (n=101)Placebo (n=100)Overall participants (n=113)
Any concomitant long-term prophylaxis“20 (20%)”“24 (24%)”“26 (23%)”
Lanadelumab“8 (8%)”“10 (10%)”“11 (10%)”
Berotralstat“5 (5%)”“7 (7%)”“7 (6%)”
C1-esterase inhibitor“4 (4%)”“5 (5%)”“5 (4%)”
Danazol“3 (3%)”“2 (2%)”“3 (3%)”